Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
asset, awaiting, broader, CI, confidence, contrast, Dana, DFCI, Farber, fixed, free, grew, interval, label, locally, mDoR, mg, mid, molecule, monotherapy, ONSEMBLE, open, PFS, Pittsburgh, proceeding, randomized, receive, received, relapsed, scan, SCLC, secondary, single, small, SOC, stage, subgroup, superior, TNBC, topline, triple, unresectable, UPMC, visit
Removed:
acetate, American, announced, antigen, antimicrotubule, arrest, assessed, Beth, compound, ctDNA, cycle, decline, division, genomic, Historically, Hospital, inducing, Israel, leasing, mCRPC, mechanism, mitotic, MOA, observe, overexpressed, population, portion, prednisone, proliferation, prostate, protocol, PSA, sensitivity, separate, showing, signaling, stabilization, sublease, subleased, sublessor, vacated
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view